Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GAPPER = HOFF
HOFF and NGS on oil momo watch!!!!!!!!
HOFF new HOD !! watch those long dormant oils hotlink they could move big tomorrow
OPBL nice one!
HOFF new HOD nice uptrending chart
can you post a HOFF chart when you can bb_stocks? thanks
HOFF starting to move tuna
in HOFF
OMPI nice move, the gift that keeps on giving lol
NGS nice chart, possible gap filler back to $16
NGS what's the short% ? Could be a good one.
NGS good find, in some here
BTJ busting out tuna, back on IBD 100!
BTJ busting a move, back on IBD 100
BTJ blowing up, back on IBD 100
MFRI me too Barbara - I think that this stock has legs and is headed to re-test and possibly break the old $26.81 highs of a month and a half ago. $100MIL in backlog - a good portion of that should be accretive to next earnings as well imo.
It tore throught the 50DMA Friday like it wasn't even there and closed right at the highs. 3.69M float
IBD has the stock pegged with an impressive 90 75 99 rating in the "Nasdaq stocks on the move" section of the weekend edition.
- Qix
RMBS what a turnaround, anyone buy in the $17s the other day?
MFRI hod close $19.69 , also FTEK nice late day move
MFRI another big HOD close {{OVER}} the 50DMA, $19.69
Are you a believer now? lol j/k
CNLG squeezin'
CNLG boucing tuna, keep an eye
CNLG 3.23
CNLG moving.. shhhhhhhhhhhh
BLTI huge news with P&G, float 24% short =>
BIOLASE Signs Definitive License Agreement With Procter & Gamble for Consumer Products
Thursday January 25, 7:30 am ET
IRVINE, CA--(MARKET WIRE)--Jan 25, 2007 -- BIOLASE Technology, Inc. (NASDAQ:BLTI - News), the world's leading dental laser company, announced today that it has signed a definitive license agreement with The Procter & Gamble Company (NYSE:PG - News) ("P&G"). Under the terms of the agreement, BIOLASE has granted P&G rights to certain BIOLASE intellectual property for use in the development of consumer products in a number of different areas. As previously announced, the companies entered into a binding letter agreement in June 2006 setting forth the terms and conditions that would be incorporated into a definitive agreement.
ADVERTISEMENT
Upon execution of the binding letter agreement, P&G paid BIOLASE an upfront fee of $3.0 million. As contemplated in the binding letter agreement, the definitive license agreement provides that P&G will pay BIOLASE royalties based on product sales, milestone payments, and quarterly payments of $250,000 until the first product is launched, a portion of which will be credited against future royalties.
BIOLASE President and CEO Jeffrey W. Jones said, "This agreement with Procter & Gamble opens the door for BIOLASE to participate in the consumer market alongside a proven leader in consumer products. We look forward to P&G bringing to the market new consumer products through this relationship."
Further details of the agreement will be included in a corresponding filing by BIOLASE with the Securities and Exchange Commission.
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc. (http://www.biolase.com), the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and medicine. The Company's products incorporate patented and patent pending technologies focused on reducing pain and improving clinical results. Its primary product, the Waterlase® system, is one of the best selling dental laser systems. The Waterlase system uses a patented combination of water and laser to precisely cut hard tissue, such as bone and teeth, and soft tissue, such as gums, with minimal or no damage to surrounding tissue. The Company also offers the LaserSmile(TM) system, which uses a laser to perform soft tissue and cosmetic procedures, including teeth whitening. The Company is also developing a laser for use in the field of ophthalmology.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
Contact:
For further information, please contact:
Jeffrey W. Jones
President & CEO
Richard L. Harrison
Executive Vice President and CFO
BIOLASE Technology, Inc.
+1-949-361-1200
Jill Bertotti
Allen & Caron
+1-949-474-4300
--------------------------------------------------------------------------------
Source: BIOLASE Technology, Inc.
CNLG watch the swing trade here, support @ $3
CNLG !!!! BLTI !!!!! watch these
back in CNLG for the swing
BIOLASE Signs Definitive License Agreement With Procter & Gamble for Consumer Products
Thursday January 25, 7:30 am ET
IRVINE, CA--(MARKET WIRE)--Jan 25, 2007 -- BIOLASE Technology, Inc. (NASDAQ:BLTI - News), the world's leading dental laser company, announced today that it has signed a definitive license agreement with The Procter & Gamble Company (NYSE:PG - News) ("P&G"). Under the terms of the agreement, BIOLASE has granted P&G rights to certain BIOLASE intellectual property for use in the development of consumer products in a number of different areas. As previously announced, the companies entered into a binding letter agreement in June 2006 setting forth the terms and conditions that would be incorporated into a definitive agreement.
ADVERTISEMENT
Upon execution of the binding letter agreement, P&G paid BIOLASE an upfront fee of $3.0 million. As contemplated in the binding letter agreement, the definitive license agreement provides that P&G will pay BIOLASE royalties based on product sales, milestone payments, and quarterly payments of $250,000 until the first product is launched, a portion of which will be credited against future royalties.
BIOLASE President and CEO Jeffrey W. Jones said, "This agreement with Procter & Gamble opens the door for BIOLASE to participate in the consumer market alongside a proven leader in consumer products. We look forward to P&G bringing to the market new consumer products through this relationship."
Further details of the agreement will be included in a corresponding filing by BIOLASE with the Securities and Exchange Commission.
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc. (http://www.biolase.com), the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and medicine. The Company's products incorporate patented and patent pending technologies focused on reducing pain and improving clinical results. Its primary product, the Waterlase® system, is one of the best selling dental laser systems. The Waterlase system uses a patented combination of water and laser to precisely cut hard tissue, such as bone and teeth, and soft tissue, such as gums, with minimal or no damage to surrounding tissue. The Company also offers the LaserSmile(TM) system, which uses a laser to perform soft tissue and cosmetic procedures, including teeth whitening. The Company is also developing a laser for use in the field of ophthalmology.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
Contact:
For further information, please contact:
Jeffrey W. Jones
President & CEO
Richard L. Harrison
Executive Vice President and CFO
BIOLASE Technology, Inc.
+1-949-361-1200
Jill Bertotti
Allen & Caron
+1-949-474-4300
--------------------------------------------------------------------------------
Source: BIOLASE Technology, Inc.
BLTI huge news with P&G tuna, float 24 % short!!
BIOLASE Signs Definitive License Agreement With Procter & Gamble for Consumer Products
Thursday January 25, 7:30 am ET
IRVINE, CA--(MARKET WIRE)--Jan 25, 2007 -- BIOLASE Technology, Inc. (NASDAQ:BLTI - News), the world's leading dental laser company, announced today that it has signed a definitive license agreement with The Procter & Gamble Company (NYSE:PG - News) ("P&G"). Under the terms of the agreement, BIOLASE has granted P&G rights to certain BIOLASE intellectual property for use in the development of consumer products in a number of different areas. As previously announced, the companies entered into a binding letter agreement in June 2006 setting forth the terms and conditions that would be incorporated into a definitive agreement.
ADVERTISEMENT
Upon execution of the binding letter agreement, P&G paid BIOLASE an upfront fee of $3.0 million. As contemplated in the binding letter agreement, the definitive license agreement provides that P&G will pay BIOLASE royalties based on product sales, milestone payments, and quarterly payments of $250,000 until the first product is launched, a portion of which will be credited against future royalties.
BIOLASE President and CEO Jeffrey W. Jones said, "This agreement with Procter & Gamble opens the door for BIOLASE to participate in the consumer market alongside a proven leader in consumer products. We look forward to P&G bringing to the market new consumer products through this relationship."
Further details of the agreement will be included in a corresponding filing by BIOLASE with the Securities and Exchange Commission.
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc. (http://www.biolase.com), the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and medicine. The Company's products incorporate patented and patent pending technologies focused on reducing pain and improving clinical results. Its primary product, the Waterlase® system, is one of the best selling dental laser systems. The Waterlase system uses a patented combination of water and laser to precisely cut hard tissue, such as bone and teeth, and soft tissue, such as gums, with minimal or no damage to surrounding tissue. The Company also offers the LaserSmile(TM) system, which uses a laser to perform soft tissue and cosmetic procedures, including teeth whitening. The Company is also developing a laser for use in the field of ophthalmology.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
Contact:
For further information, please contact:
Jeffrey W. Jones
President & CEO
Richard L. Harrison
Executive Vice President and CFO
BIOLASE Technology, Inc.
+1-949-361-1200
Jill Bertotti
Allen & Caron
+1-949-474-4300
--------------------------------------------------------------------------------
Source: BIOLASE Technology, Inc.
*** BLTI *** BIOLASE Signs Definitive License Agreement With Procter & Gamble for Consumer Products
Thursday January 25, 7:30 am ET
IRVINE, CA--(MARKET WIRE)--Jan 25, 2007 -- BIOLASE Technology, Inc. (NASDAQ:BLTI - News), the world's leading dental laser company, announced today that it has signed a definitive license agreement with The Procter & Gamble Company (NYSE:PG - News) ("P&G"). Under the terms of the agreement, BIOLASE has granted P&G rights to certain BIOLASE intellectual property for use in the development of consumer products in a number of different areas. As previously announced, the companies entered into a binding letter agreement in June 2006 setting forth the terms and conditions that would be incorporated into a definitive agreement.
ADVERTISEMENT
Upon execution of the binding letter agreement, P&G paid BIOLASE an upfront fee of $3.0 million. As contemplated in the binding letter agreement, the definitive license agreement provides that P&G will pay BIOLASE royalties based on product sales, milestone payments, and quarterly payments of $250,000 until the first product is launched, a portion of which will be credited against future royalties.
BIOLASE President and CEO Jeffrey W. Jones said, "This agreement with Procter & Gamble opens the door for BIOLASE to participate in the consumer market alongside a proven leader in consumer products. We look forward to P&G bringing to the market new consumer products through this relationship."
Further details of the agreement will be included in a corresponding filing by BIOLASE with the Securities and Exchange Commission.
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc. (http://www.biolase.com), the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and medicine. The Company's products incorporate patented and patent pending technologies focused on reducing pain and improving clinical results. Its primary product, the Waterlase® system, is one of the best selling dental laser systems. The Waterlase system uses a patented combination of water and laser to precisely cut hard tissue, such as bone and teeth, and soft tissue, such as gums, with minimal or no damage to surrounding tissue. The Company also offers the LaserSmile(TM) system, which uses a laser to perform soft tissue and cosmetic procedures, including teeth whitening. The Company is also developing a laser for use in the field of ophthalmology.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
Contact:
For further information, please contact:
Jeffrey W. Jones
President & CEO
Richard L. Harrison
Executive Vice President and CFO
BIOLASE Technology, Inc.
+1-949-361-1200
Jill Bertotti
Allen & Caron
+1-949-474-4300
--------------------------------------------------------------------------------
Source: BIOLASE Technology, Inc.
Novellus Systems 4th-Quarter Profit Doubles on 32 Percent Jump in Revenue
SAN JOSE, Calif. (AP) -- Semiconductor equipment maker Novellus Systems Inc. said Wednesday its fourth-quarter profit nearly doubled as sales surged.
The company earned $42.6 million, or 34 cents per share, compared with profit of $23 million, or 17 cents per share, during the year-ago quarter.
Excluding a $46.1 million restructuring charge and other items, income in the latest quarter would have been 63 cents per share.
Analysts polled by Thomson Financial expected profit of 55 cents per share during the quarter.
Revenue jumped 32 percent to $438.5 million from $332.3 million. Analysts expected revenue of $436.4 million.
For the full year, the profit rose 73 percent to $190 million from $110.1 million while revenue jumped 24 percent to $1.66 billion from $1.34 billion. Earnings per share jumped to $1.50 from 80 cents.
Shares of Novellus rose 56 cents to close at $30.61 on the Nasdaq.
>>> Novellus huge earnings here tuna, keep watch!
Novellus Systems 4th-Quarter Profit Doubles on 32 Percent Jump in Revenue
SAN JOSE, Calif. (AP) -- Semiconductor equipment maker Novellus Systems Inc. said Wednesday its fourth-quarter profit nearly doubled as sales surged.
The company earned $42.6 million, or 34 cents per share, compared with profit of $23 million, or 17 cents per share, during the year-ago quarter.
Excluding a $46.1 million restructuring charge and other items, income in the latest quarter would have been 63 cents per share.
Analysts polled by Thomson Financial expected profit of 55 cents per share during the quarter.
Revenue jumped 32 percent to $438.5 million from $332.3 million. Analysts expected revenue of $436.4 million.
For the full year, the profit rose 73 percent to $190 million from $110.1 million while revenue jumped 24 percent to $1.66 billion from $1.34 billion. Earnings per share jumped to $1.50 from 80 cents.
Shares of Novellus rose 56 cents to close at $30.61 on the Nasdaq.
big gap up in CPSL this morning, can't see any news?
watch NVLS, this one's headed back to $35 imo blowout .63 vs .20 numbers ex items
NVLS moving AH on strong earnings:
Novellus Systems Reports Fourth Quarter and Year-End Results
Wednesday January 24, 4:05 pm ET
SAN JOSE, Calif., Jan. 24 /PRNewswire-FirstCall/ -- Novellus Systems, Inc. (Nasdaq: NVLS - News) today reported net sales and results of operations for its fourth quarter and year ended December 31, 2006. Net sales for the fourth quarter were $438.5 million, down $5.5 million or 1.2 percent from third quarter 2006 net sales of $444.0 million, and up $106.2 million or 32.0 percent from fourth quarter 2005 net sales of $332.3 million. Net income for the fourth quarter was $42.6 million, or $0.34 per diluted share, down $27.4 million or 39.2 percent from third quarter 2006 net income of $70.0 million, and up $19.6 million or 85.2 percent from fourth quarter 2005 net income of $23.0 million.
ADVERTISEMENT
The fourth quarter results reflect a $1.9 million pre-tax reversal of a previously recorded restructuring accrual resulting primarily from a change in estimated sublease income over the remaining lease term. Also recorded in the fourth quarter was a tax charge of $46.1 million related to the planned implementation of a new global business structure. In future years we expect to achieve a lower tax rate, as well as business efficiencies, as a result of this new business structure. The tax charge was partially offset by an $8.5 million tax benefit attributable to the settlement of an IRS audit. As a result, the fourth quarter tax rate was 62.3%. The fourth quarter 2006 net income would have been $79.0 million, or $0.63 per diluted share, excluding these items. The third quarter 2006 results did not include any unusual charges or benefits. The fourth quarter 2005 results reflect net pre-tax restructuring and other charges of $5.9 million. Without the restructuring charges, fourth quarter 2005 net income would have been $26.6 million, or $0.20 per diluted share. A reconciliation of pro forma operating results to U.S. generally accepted accounting principals ("GAAP") results is included in the financial statements below.
Net sales for the fiscal year 2006 were $1.66 billion, up $318.0 million or 23.7% compared with net sales of $1.34 billion in fiscal year 2005. Net income for the year was $190.0 million or $1.50 per diluted share, compared with fiscal year 2005 net income of $110.1 million, or $0.80 per diluted share.
The fiscal year 2006 results include a pre-tax benefit of $1.5 million from the cumulative effect of a change in accounting principle due to the adoption of SFAS 123®, a pre-tax net restructuring charge of $10.7 million, a pre-tax charge of $3.3 million for a legal settlement and the $46.1 million tax charge and $8.5 million tax benefit discussed above. Without these charges and benefits, net income for 2006 would have been $235.3 million, or $1.86 per diluted share. In comparison, the fiscal year 2005 results included pre-tax net restructuring charges of $9.2 million and a pre-tax inventory write-down of $5.3 million. Without these charges net income, for 2005 would have been $118.9 million, or $0.86 per diluted share.
Bookings in the fourth quarter were $441.6 million, down 6.1 percent over third quarter 2006 bookings of $470.3 million. Shipments of $390.2 million in the fourth quarter represent a decrease of $24.1 million or 5.8 percent from $414.2 million reported for the third quarter 2006. Deferred revenue at the end of the fourth quarter was $100.3 million, a decrease of $48.3 million or 32.5 percent from $148.6 million at the end of the third quarter of 2006.
Cash, cash equivalents, restricted cash and short-term investments as of December 31, 2006 were $993.2 million, an increase of $179.9 million or 22.1 percent from the third quarter of 2006 ending balance of $813.3 million.
The financial measures set forth above that present net income excluding certain charges and benefits, revenue on a shipments basis and bookings, are not in accordance with GAAP. The Company believes that these non-GAAP financial measures provide further insight into the results of operations and enhance the consistency and comparability of those results to results in prior periods because they assist shareholder understanding of the effects of certain charges and benefits on the quarter's results.
"2006 was a record year for bookings, shipments and revenues", said Richard S. Hill, chairman of the board and CEO. "In addition to our strong top line growth, we significantly improved our bottom line performance as a result of the initiatives we have taken to strengthen our product portfolio and improve our financial operating model."
RMBS neutral after hours
RMBS flying into earnings
MFRI it exploded past the opening gap on volume after re-testing the previous lows on low volume this morning, that's what I mean.
Technical breakout!!
MFRI huge
keep an eye on RMBS tuna, earnings after the bell and up big right now ;)
VGNI !!!!!!! VGNI exploding on news !!!!!!!!!